Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

NCT01342172 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped low accrual

Conditions

Urinary Bladder Neoplasms

Interventions

DRUG: Lenalidomide

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

[object Object]